Oral Novo Nordisk diabetes drug poses no more heart risk than placebo study

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday. ...

More From BioPortfolio on "Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study"